Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Account Payables: 2013-2024

Historic Change in Account Payables for Collegium Pharmaceutical (COLL) over the last 12 years, with Dec 2024 value amounting to -$11.3 million.

  • Collegium Pharmaceutical's Change in Account Payables rose 44.77% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 162.85%. This contributed to the annual value of -$11.3 million for FY2024, which is 322.84% down from last year.
  • As of FY2024, Collegium Pharmaceutical's Change in Account Payables stood at -$11.3 million, which was down 322.84% from $5.1 million recorded in FY2023.
  • In the past 5 years, Collegium Pharmaceutical's Change in Account Payables ranged from a high of $5.1 million in FY2023 and a low of -$11.3 million during FY2024.
  • For the 3-year period, Collegium Pharmaceutical's Change in Account Payables averaged around -$2.3 million, with its median value being -$707,000 (2022).
  • In the last 5 years, Collegium Pharmaceutical's Change in Account Payables skyrocketed by 815.84% in 2023 and then crashed by 322.84% in 2024.
  • Collegium Pharmaceutical's Change in Account Payables (Yearly) stood at $3.8 million in 2020, then slumped by 254.60% to -$5.8 million in 2021, then skyrocketed by 87.87% to -$707,000 in 2022, then surged by 815.84% to $5.1 million in 2023, then slumped by 322.84% to -$11.3 million in 2024.